

# Utilization of Potential Paxlovid Interactors

## among Paxlovid-eligible COVID-19 Patients or Patients with a Paxlovid Exposure

### RETROSPECTIVE COHORT STUDY



**Objective:** Estimate the magnitude of the “at-risk” population using drugs that interact with Paxlovid to inform the Division of Antiviral’s labeling decision




Rapid Sentinel Distributed Database



December 2021 – December 2022



1. Individuals with outpatient diagnosis of COVID-19 and no prior evidence of severe renal or hepatic impairment
2. Individuals with use of Paxlovid



	COVID among Patients ≥65 years or High-risk		COVID among Patients ≥50 years or High-risk		Paxlovid Users	
Total number of patients	1,228,761		1,450,712		551,482	
Any Drug that Interacts with Paxlovid	695,320	56.6%	763,727	52.6%	310,012	56.2%
Any Drugs Contraindicated for use with Paxlovid	89,916	7.3%	95,400	6.6%	37,929	6.9%
Any Drugs to be avoided with paxlovid	354,035	28.8%	379,286	26.1%	167,996	30.5%
Any Other Drug Drug Interactor	508,854	41.4%	557,654	38.4%	211,257	38.3%



- >50% of Paxlovid eligible users could have taken drugs that could interact with Paxlovid\*
- Commonly used Paxlovid interactors are unlikely to prevent Paxlovid use
- 7% of Paxlovid users may have used contraindicated drugs and 31% may have used drugs that should be avoided with Paxlovid\*



Query results were included in Paxlovid NDA review.

\* Health insurance claims data do not capture if concurrent medications were withheld or had their dose adjusted due to Paxlovid